Prior Clinical Trials

The technology has extensive clinical experience in melanoma. Provided below are overviews of two randomized Phase 2 clinical trials that have been completed, plus comparative historical analysis.

Polynoma’s primary technology, seviprotimut-L, was formerly known as POL-103A